Drug Profile
Relacorilant - Corcept Therapeutics
Alternative Names: CORT-125134Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Class Antineoplastics; Fluorine compounds; Isoquinolines; Ketones; Organic sulfur compounds; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cushing syndrome; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Phase II Prostate cancer
- Phase I/II Solid tumours
- No development reported Adrenocortical carcinoma
Most Recent Events
- 08 Apr 2024 Corcept Therapeutics completes enrolment in its phase III ROSELLA trial for Peritoneal cancer, Fallopian tube cancer and Ovarian cancer (Late-stage disease, Second-line or greater, Recurrent, Combination therapy) in USA, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, South Korea, Poland, Spain, United kingdom (NCT05257408)
- 01 Apr 2024 Corcept Therapeutics completes the enrolment in the phase III GRADIENT trial for Cushing syndrome in Austria, Bulgaria, Israel, Italy, Poland, Romania, Spain and Germany (PO) (NCT04308590) (EudraCT2019-004956-12)
- 12 Jan 2024 Corcept Therapeutics completes a phase I clinical trial in Adenocarcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (PO) (NCT04373265)